Back to Journals » International Journal of Nanomedicine » Volume 13 » T-NANO 2014 Abstracts

Oral bioavailability enhancement of agomelatine by loading into nanostructured lipid carriers: Peyer’s patch targeting approach

Authors Prajapati JB, Verma SD, Patel AA

Received 14 October 2016

Accepted for publication 21 November 2016

Published 15 March 2018 Volume 2018:13(T-NANO 2014 Abstracts) Pages 35—38


Checked for plagiarism Yes

Review by Single anonymous peer review

Peer reviewer comments 2

Editor who approved publication: Dr Lei Yang

Jagruti B Prajapati, Sneha D Verma, Amit A Patel

Department of Ppharmaceutics and Ppharmaceutical Technology, Rramanbhai Patel College of Ppharmacy, Charotar University of Science and Technology, Changa, Gujarat, India

Abstract: Agomelatine (AGM) is a new antidepressant drug with a novel mechanism of action and fewer side effects compared with older antidepressants. AGM is a melatonin receptor (MT1 and MT2) agonist and 5-hydroxytryptamine receptor (5-HT2C) antagonist. In the present study, the enhancement of the oral bioavailability of AGM was formulated and loaded into nanostructured lipid carriers (NLCs), using ultrasonication method. In vitro and ex vivo drug release was performed using a dialysis bag and rat duodenum, respectively. Our pharmacodynamic study showed that AGM–NLCs are more efficacious than a pure drug and marketed product, and confocal microscopy revealed lymphatic uptake of AGM–NLCs. The present study concluded that the NLCs enhanced the oral bioavailability of AGM (6.5-fold) by avoiding its first-pass metabolism by way of lymphatic uptake.

Keywords: agomelatine, nanostructured lipid carriers, antidepressant drug

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]